Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30773494 | 1.00 | ELANE (0.52) | ELANENUDT1CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL31694921 | 0.77 | ELANE (0.49) | ELANENUDT1ALDH1A1HSD17B10TSHR | |
| SCHEMBL18548985 | 0.77 | ELANE (0.49) | ELANENUDT1ALDH1A1HSD17B10TSHR | |
| SCHEMBL10045313 | 0.76 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL2517690 | 0.76 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL28594146 | 0.76 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL29948066 | 0.76 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL17153835 | 0.76 | CYP3A4 (0.42) | CYP3A4ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL2490973 | 0.76 | KMT2A (0.58) | ELANECYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL29728164 | 0.76 | KMT2A (0.58) | ELANECYP3A4ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165173-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885CYP3A4 2112/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | ELANE 880/4885NUDT1 1017/4885CYP3A4 1659/4885 |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885CYP3A4 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.